cardiac-blood-collection-via-subclavian-puncture-in-mice

Cardiac Blood Collection via Subclavian Puncture in Mice

In experimental studies, mouse blood is a common experimental sample. However, there are still some challenges for the collection of large volumes of ...

Yanbian University

Myocardial infarction (MI) is a highly challenging and fatal disease, with diverse challenges arising at different stages of its progression. As such, non-coding RNAs (ncRNAs), which can broadly regulate cell fate, and stem cells with multi-differentiation potential are emerging as novel therapeutic approaches for treating MI across its various stages. NcRNAs, including microRNAs (miRNAs) and long non-coding RNAs (LncRNAs), can directly participate in regulating intracellular signaling pathways, influence cardiac angiogenesis, and promote the repair of infarcted myocardium. Currently, stem cells commonly used in medicine, such as mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs), can differentiate into various human cell types without ethical concerns. When combined with ncRNAs, these stem cells can more effectively induce directed differentiation, promote angiogenesis in the infarcted heart, and replenish normal cardiac cells. Additionally, stem cell-derived exosomes, which contain various ncRNAs, can improve myocardial damage in the infarcted region through paracrine mechanisms. However, our understanding of the specific roles and mechanisms of ncRNAs, stem cells, and exosomes secreted by stem cells during different stages of MI remains limited. Therefore, this review systematically categorizes the different stages of MI, aiming to summarize the direct regulatory effects of ncRNAs on an infarcted myocardium at different points of disease progression. Moreover, it explores the specific roles and mechanisms of stem cell therapy and exosome therapy in this complex pathological evolution process. The objective of this review was to provide novel insights into therapeutic strategies for different stages of MI and open new research directions for the application of stem cells and ncRNAs in the field of MI repair.

Innovative Therapeutic Strategies for Myocardial Infarction Across Various Stages: Non-Coding RNA and Stem Cells.

Atrial natriuretic peptide (ANP) and Zn have been shown to confer cardioprotection against ischemia/reperfusion (I/R) injury. Zn alleviates myocardial hypertrophy and pulmonary hypertension by regulating ANP expression, but its precise role in ANP-mediated cardioprotection remains unclear. This study aimed to investigate whether ANP protects the heart during reperfusion by modulating Zn levels and to explore the underlying mechanisms involved.

ANP Increases Zn Accumulation During Reperfusion in Ex Vivo and In Vivo Hearts.

Myocardial infarction (MI) and myocardial ischemia-reperfusion injury (MIRI) are major pathological conditions in cardiovascular disease, requiring in-depth study for effective therapy development. Here, we present a detailed protocol for establishing a mouse model using the squeeze technique to simulate MI and MIRI. Key steps include isoflurane-induced anesthesia, left anterior descending artery (LAD) ligation, and real-time monitoring. Additionally, we describe procedures for histological analysis, offering a comprehensive approach to investigating disease mechanisms and potential therapeutic strategies. For complete details on the use and execution of this protocol, please refer to Gao et al..

Article	Year
Innovative Therapeutic Strategies for Myocardial Infarction Across Various Stages: Non-Coding RNA and Stem Cells. International journal of molecular sciences\| PubMed ID: 39796085	2024
ANP Increases Zn Accumulation During Reperfusion in Ex Vivo and In Vivo Hearts. Current medical science\| PubMed ID: 40014195	2025
Protocol for the establishment of a mouse myocardial infarction and ischemia-reperfusion model via heart compression. STAR protocols\| PubMed ID: 40184247	2025

Hailian Quan

Biography

JoVE Journal Publications

Other Publications